Research Article
Epidemiological Profile of Urinary Lithiasis in the Urology Department of Libreville University Hospital from January 2020 to September 2024
Ndang Ngou Milama Steevy*
,
Adande Menest Elvire Felicite,
Mbethe Dimitri,
Mougougou Adrien,
Abeme Lesly,
Bissiriou Izoudine,
Nguyen Akendengue Leslie,
Allogho Mbouye Gloire
Issue:
Volume 10, Issue 2, December 2026
Pages:
114-118
Received:
1 June 2026
Accepted:
17 June 2026
Published:
24 July 2026
Abstract: Introduction: Urinary stone disease is a common condition. They mainly form in the kidney but can occur anywhere in the urinary tract, leading to complications that can be serious. The aim of this study was to determine the epidemiological profile of urinary stone disease in the Urology Department of the Libreville University Hospital Center (CHUL) from 2020 to 2024. Materials and Methods: This is a retrospective descriptive study of patients treated for urinary lithiasis in the Urology Department of the CHUL between January 1, 2020, and September 30, 2024. Results: 184 patients were hospitalized during the study period for urinary lithiasis. The mean age was 42 ± 16.2 years, ranging from 11 to 85 years, and the sex ratio was 1: 1. Renal colic was the presenting symptom in 84.2% of cases. The stones were located in the upper urinary tract in 77.7% of cases. CT urography was performed in 90.2% of cases. The stones measured an average of 15.2 mm and were complicated in 50.5% of cases, including hydronephrosis (23.9%) followed by ureterohydronephrosis (19%). Conclusion: Urinary lithiasis is a common condition predominantly located in the upper urinary tract. This condition most often affects young, professionally active adults. The presence of serious complications highlights the need for earlier diagnosis of this condition.
Abstract: Introduction: Urinary stone disease is a common condition. They mainly form in the kidney but can occur anywhere in the urinary tract, leading to complications that can be serious. The aim of this study was to determine the epidemiological profile of urinary stone disease in the Urology Department of the Libreville University Hospital Center (CHUL)...
Show More
Research Article
Silodosin in the Management of Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms:
An Experts Perspective Study
Manjula Suresh*,
Krishna Kumar Manjunath
Issue:
Volume 10, Issue 2, December 2026
Pages:
119-125
Received:
2 July 2026
Accepted:
16 July 2026
Published:
10 August 2026
DOI:
10.11648/j.ijcu.20261002.12
Downloads:
Views:
Abstract: Background: Benign prostatic hyperplasia (BPH) commonly causes lower urinary tract symptoms (LUTS), with α1-blockers as first-line therapy. Silodosin, due to its high uroselectivity and favorable tolerability, is increasingly used; this survey assesses clinician preferences, usage patterns, tolerability, and combination therapy practices in clinical practice. Methods: This cross-sectional survey was conducted among 97 urologists in India and used a validated 23-item questionnaire to assess treatment preferences, silodosin use, switching patterns, adverse events, combination therapies, and outcomes. Data were analyzed descriptively as frequencies and percentages. Results: The survey included 97 participants. A majority of clinicians (76%) preferred silodosin as the first-line α1-blocker for BPH management. Approximately 44% recognized all listed reasons for its use, including receptor selectivity, safety profile, and clinical benefits. Switching from tamsulosin to silodosin in 21–30% of patients due to inadequate symptom relief was reported by around 43% of clinicians. Marked clinical improvement with silodosin was observed by nearly 77%, while 54% reported no associated adverse drug reactions. Reduction in the risk of BPH-related surgery was identified as the key advantage of combination therapy by around 47% of clinicians. Preference for the silodosin and dutasteride combination to prevent disease progression was noted by 85% of respondents, and approximately 53% reported adding mirabegron to silodosin in 11–20% of patients. Conclusion: This survey highlights silodosin as an effective, well-tolerated, and first-line treatment for BPH and LUTS in clinical practice. Its high uroselectivity, favorable safety profile, and strong symptomatic relief support its use both as monotherapy and in combination with dutasteride or mirabegron in more complex cases. These findings underscore the need for further long-term studies to strengthen its role in BPH management.
Abstract: Background: Benign prostatic hyperplasia (BPH) commonly causes lower urinary tract symptoms (LUTS), with α1-blockers as first-line therapy. Silodosin, due to its high uroselectivity and favorable tolerability, is increasingly used; this survey assesses clinician preferences, usage patterns, tolerability, and combination therapy practices in clinica...
Show More
